BACKGROUND: The role of apoptosis in the regression of human prostate cancer after androgen deprivation therapy remains controversial. Detection of caspase-3, an ubiquitous effector of apoptosis, is a highly specific technique for in vivo evaluation of apoptosis. METHODS: Apoptotic rates were evaluated in the androgen-dependent CWR22 human prostate cancer xenograft in tumors that represented time points throughout the progression from androgen-stimulated to recurrent prostate cancer. Caspase-3 levels in formalin-fixed, paraffin-embedded specimens were quantified using immunohistochemical detection and video image analysis. Western blot analysis was used to confirm the results of immunodetection. RESULTS: Expression of caspase-3 reached a maximum on day 2 after castration, decreased on day 6, and remained low until tumor recurrence. The percentage of tumor area expressing caspase-3 increased from 2.51 +/- 0.44% in tumors from intact mice to 20.84 +/- 1.75% on day 2 after castration. Among immunopositive cells, the intensity of caspase-3 expression measured using the mean optical density (MOD) increased 45% (0.3762 +/- 0.003 to 0.5461 +/- 0.001) on day 2 after castration compared to levels detected in tumors from intact mice. CONCLUSIONS: Apoptosis contributes to tumor regression after castration in the CWR22 human prostate cancer xenograft model. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: The role of apoptosis in the regression of humanprostate cancer after androgen deprivation therapy remains controversial. Detection of caspase-3, an ubiquitous effector of apoptosis, is a highly specific technique for in vivo evaluation of apoptosis. METHODS: Apoptotic rates were evaluated in the androgen-dependent CWR22 humanprostate cancer xenograft in tumors that represented time points throughout the progression from androgen-stimulated to recurrent prostate cancer. Caspase-3 levels in formalin-fixed, paraffin-embedded specimens were quantified using immunohistochemical detection and video image analysis. Western blot analysis was used to confirm the results of immunodetection. RESULTS: Expression of caspase-3 reached a maximum on day 2 after castration, decreased on day 6, and remained low until tumor recurrence. The percentage of tumor area expressing caspase-3 increased from 2.51 +/- 0.44% in tumors from intact mice to 20.84 +/- 1.75% on day 2 after castration. Among immunopositive cells, the intensity of caspase-3 expression measured using the mean optical density (MOD) increased 45% (0.3762 +/- 0.003 to 0.5461 +/- 0.001) on day 2 after castration compared to levels detected in tumors from intact mice. CONCLUSIONS: Apoptosis contributes to tumor regression after castration in the CWR22 humanprostate cancer xenograft model. Copyright 2003 Wiley-Liss, Inc.
Authors: Jonathan A Ewald; Joshua A Desotelle; Dawn R Church; Bing Yang; Wei Huang; Timo A Laurila; David F Jarrard Journal: Prostate Date: 2012-08-21 Impact factor: 4.104
Authors: Young A Yoo; Meejeon Roh; Anum F Naseem; Barbara Lysy; Mohamed M Desouki; Kenji Unno; Sarki A Abdulkadir Journal: Nat Commun Date: 2016-10-05 Impact factor: 14.919
Authors: Michael L Blute; Nathan Damaschke; Jennifer Wagner; Bing Yang; Martin Gleave; Ladan Fazli; Fangfang Shi; E Jason Abel; Tracy M Downs; Wei Huang; David F Jarrard Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240